JUPITOR-02: Randomized, Double-Blind, Phase 3 Study of Toripalimab or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

医学 危险系数 内科学 安慰剂 临床终点 吉西他滨 中期分析 肿瘤科 中止 胃肠病学 化疗 置信区间 外科 不利影响 随机对照试验 病理 替代医学
作者
Hai‐Qiang Mai,Qiu-Yan Chen,Dongping Chen,Chaosu Hu,Kunyu Yang,Jiyu Wen,Jingao Li,Ying-Rui Shi,Feng Jin,Ruilian Xu,Jianji Pan,Shenhong Qu,Ping Li,Chunhong Hu,Yi‐Chun Liu,Yi Jiang,Xia He,Hung-Ming Wang,Wangjun Liao,Wangjun Liao
出处
期刊:Nature Medicine [Nature Portfolio]
卷期号:27 (9): 1536-1543 被引量:417
标识
DOI:10.1038/s41591-021-01444-0
摘要

Gemcitabine-cisplatin (GP) chemotherapy is the standard first-line systemic treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In this international, double-blind, phase 3 trial (ClinicalTrials.gov identifier: NCT03581786), 289 patients with RM-NPC and no previous chemotherapy for recurrent or metastatic disease were randomized (1/1) to receive either toripalimab, a monoclonal antibody against human programmed death-1 (PD-1), or placebo in combination with GP every 3 weeks for up to six cycles, followed by monotherapy with toripalimab or placebo. The primary endpoint was progression-free survival (PFS) as assessed by a blinded independent review committee according to RECIST v.1.1. At the prespecified interim PFS analysis, a significant improvement in PFS was detected in the toripalimab arm compared to the placebo arm: median PFS of 11.7 versus 8.0 months, hazard ratio (HR) = 0.52 (95% confidence interval (CI): 0.36–0.74), P = 0.0003. An improvement in PFS was observed across key subgroups, including PD-L1 expression. As of 18 February 2021, a 40% reduction in risk of death was observed in the toripalimab arm compared to the placebo arm (HR = 0.603 (95% CI: 0.364–0.997)). The incidence of grade ≥3 adverse events (AEs) (89.0 versus 89.5%), AEs leading to discontinuation of toripalimab/placebo (7.5 versus 4.9%) and fatal AEs (2.7 versus 2.8%) was similar between the two arms; however, immune-related AEs (39.7 versus 18.9%) and grade ≥3 infusion reactions (7.5 versus 0.7%) were more frequent in the toripalimab arm. In conclusion, the addition of toripalimab to GP chemotherapy as a first-line treatment for patients with RM-NPC provided superior PFS compared to GP alone, and with a manageable safety profile. Interim analysis from the randomized phase 3 JUPITER-02 trial shows that the addition of anti-PD-1 toripalimab to standard gemcitabine/cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma has manageable toxicity and improves progression-free survival, suggesting a potential new treatment standard in this setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
希妍完成签到,获得积分10
1秒前
醉熏的灵完成签到,获得积分10
2秒前
秋风的应助被畅快的长颈鹿采纳,获得10
2秒前
脑洞疼的应助被Threeeeeee采纳,获得10
3秒前
比耶完成签到,获得积分10
3秒前
米卡完成签到,获得积分10
4秒前
4秒前
4秒前
5秒前
蜉蝣完成签到,获得积分10
5秒前
5秒前
尚语安发布了新的文献求助10
5秒前
6秒前
樱岛发布了新的文献求助10
6秒前
你好完成签到 ,获得积分10
6秒前
6秒前
7秒前
希望天下0贩的0的应助被sendou采纳,获得10
7秒前
打打的应助被XX采纳,获得10
8秒前
8秒前
9秒前
9秒前
Jxw完成签到,获得积分10
9秒前
李子发布了新的文献求助10
9秒前
马小跳完成签到,获得积分10
9秒前
张禾完成签到,获得积分10
10秒前
10秒前
木子完成签到 ,获得积分10
10秒前
Owen的应助被wsx采纳,获得10
11秒前
张火火发布了新的文献求助20
11秒前
凶狠的乐巧完成签到,获得积分10
12秒前
aqqq发布了新的文献求助10
13秒前
04d的应助被粉色棉毛裤采纳,获得10
14秒前
14秒前
MXX发布了新的文献求助10
14秒前
火星上小土豆完成签到 ,获得积分10
14秒前
14秒前
单薄小蜜蜂完成签到,获得积分10
15秒前
15秒前
无花果的应助被俏皮的翩跹采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168068
求助须知:如何正确求助?哪些是违规求助? 9561081
关于积分的说明 21759342
捐赠科研通 7759355
什么是DOI,文献DOI怎么找? 3429909
关于科研通互助平台的介绍 2553742
邀请新用户注册赠送积分活动 2474451